@article{Tarkin:2020:10.1161/CIRCIMAGING.119.010389,
author = {Tarkin, JM and Wall, C and Gopalan, D and Aloj, L and Manavaki, R and Fryer, TD and Aboagye, EO and Bennett, MR and Peters, JE and Rudd, JHF and Mason, JC},
doi = {10.1161/CIRCIMAGING.119.010389},
journal = {Circulation: Cardiovascular Imaging},
pages = {1--3},
title = {Novel approach to imaging active takayasu arteritis using somatostatin receptor positron emission tomography/magnetic resonance imaging.},
url = {http://dx.doi.org/10.1161/CIRCIMAGING.119.010389},
volume = {13},
year = {2020}
}

Download

TY  - JOUR
AB  - Although 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) is an important diagnostic test for Takayasu arteritis (TAK),118F-FDG lacks inflammatory cell selectivity and cannot accurately distinguish arteritis from metabolically active vascular remodeling.2 This observation has led to the search for more sensitive and specific PET tracers for TAK. Macrophage activation antigen SST2 (somatostatin receptor subtype-2) PET represents a potential alternative imaging biomarker for defining disease activity in TAK, as macrophages are a major feature of the inflammatory infiltrate. We aimed to determine the ability of SST2 PET/magnetic resonance imaging (MRI) to detect arteritis in 2 patients with clinically active TAK.
AU  - Tarkin,JM
AU  - Wall,C
AU  - Gopalan,D
AU  - Aloj,L
AU  - Manavaki,R
AU  - Fryer,TD
AU  - Aboagye,EO
AU  - Bennett,MR
AU  - Peters,JE
AU  - Rudd,JHF
AU  - Mason,JC
DO  - 10.1161/CIRCIMAGING.119.010389
EP  - 3
PY  - 2020///
SN  - 1941-9651
SP  - 1
TI  - Novel approach to imaging active takayasu arteritis using somatostatin receptor positron emission tomography/magnetic resonance imaging.
T2  - Circulation: Cardiovascular Imaging
UR  - http://dx.doi.org/10.1161/CIRCIMAGING.119.010389
UR  - https://www.ncbi.nlm.nih.gov/pubmed/32460529
UR  - https://www.ahajournals.org/doi/full/10.1161/CIRCIMAGING.119.010389
UR  - http://hdl.handle.net/10044/1/80444
VL  - 13
ER  - 

Download